Clinical Trials
Sep 06, 2026 · 1 min read · 22,211 views
Novartis' TREM2 drug fails Phase 2 ALS trial
E
Ethan Cole
Editorial · Sep 06, 2026
Reports indicate that the Swiss pharma giant is ending work on VHB937/lifonebart in ALS, according to a letter from the company's clinical development team
← Previous
China sets ambitious goals for global drug and biotech expansion in new five-year plan
Next →
Enveda raises its third megaround in as many years for I&I and weight maintenance drug candidates
